Shilpa Medicare Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Record quarter, harvesting thesis intact: Revenue and EBITDA hit all-time highs for the fourth straight quarter, with formulation revenue more than doubling YoY. Management’s framing is that heavy reinvestment is largely done and the business is now built to compound.
• Formulations and biologics are the growth engines: Formulations grew over 100% YoY on complex U.S. FDA products, while biologics rose 42% on licensing and CDMO momentum. Both divisions still carry low capacity utilization, so incremental revenue can flow through at high margins.
• Pipeline is deep but timelines are long: Three CDMO NCE programs enter commercialization in FY28, the first ADC biosimilar and two NBE programs enter human studies in FY27, and recombinant human albumin targets an India filing in FY28. Near-term revenue conversion depends on partners’ execution.
• Margins held near 30% despite raw material pressure: EBITDA margin stayed around 30% even as gross margin dipped on higher raw material costs that could only partly be passed through. Management wants to stay conservative and not raise expectations.
• What to watch next quarter: Whether the 3 late-stage CDMO programs stay on track for FY28 commercialization, any update on Unicycive’s CRL refiling, and how much of the formulation growth is repeatable versus lumpy licensing income.

The Harvesting Thesis

Management’s central narrative is that the heavy investment cycle is complete and the company is now entering a period where existing assets generate returns without requiring commensurate new capital.

• Capex light for three years: No significant capex is needed in Biologics or Albumin for at least the next three years; ongoing capex is limited to API and select new formulation molecules where capacity is already tight.
• Low utilization provides operating leverage: API capacity utilization is high and attracting incremental capex, but Biologics and Formulations plants are running at very low utilization, so volume growth can convert to revenue with minimal additional fixed cost.
• ROCE turning positive in new divisions: Biologics and Albumin divisions have moved from ROCE-negative to ROCE-positive over the past 1–1.5 years, though levels remain low because of the large asset base. Adjusted consolidated ROCE reached 18.3%.
• Credit rating upgrade validates the turn: The upgrade to AA- reflects the significant improvement in operations and financial performance over the past few years.

Keshav Bhutada: "In simple terms, the reinvesting is largely behind us. The harvesting is ahead of us."

Formulations: Complex Products, U.S. Led

The formulations division delivered the quarter’s most dramatic growth, driven almost entirely by a portfolio of complex, differentiated products rather than commoditized generics.

• Revenue more than doubled YoY: Formulation revenue grew over 100% YoY, with the base business (excluding licensing income) up approximately 112%, led by the complex FDA portfolio in the U.S. and supported by EU and ROW regions.
• Product selection filters for sustainability: Management explicitly avoids products that see 90–95% price erosion within months of launch. The portfolio is built around first-wave generics (Rotigotine transdermal patch), products with few generic players (Abraxane), and 505(b)(2) products with no generic competition.
• Near-term launch pipeline: Rotigotine patch is approved in Europe and filed in the U.S. with a strong partner, targeting FY28 U.S. launch. Abraxane, Enzalutamide, and Abiraterone are also on track for FY28. Three commercial 505(b)(2)s approved last year are already growing quarter-on-quarter.
• Europe revenue dip is noise, not signal: Europe revenue fell from ~INR77 crores to ~INR57 crores QoQ, but this reflects variation in tendered product supply timing, not any fundamental demand weakness.
• U.S. tariff risk is muted: Because Shilpa does not sell commoditized generics in the U.S. and all products carry complexity-based differentiation, management sees no material tariff impact. The company is evaluating U.S. manufacturing but is waiting for policy clarity.

Keshav Bhutada: "We will never do a product that sells for 1 or 6 months and then suddenly sees sales drop by 90%, 95% on pricing. Such products Shilpa will never do."

Biologics & CDMO: Early but Scaling

The biologics segment is growing off a small base with a mixed strategy: near-term biosimilars and CDMO, long-term bets on novel biologics platforms.

• Revenue up 42% YoY: Growth was driven by continued deal momentum in licensing, partnerships, and CDMO businesses.
• Biosimilar pipeline is broad: More than 5 biosimilars are in the pipeline. Aflibercept has completed clinical studies and is partnered with 3 Indian ophthalmic companies for a FY27 India launch. Nivolumab has its first European partnership (Orion Corporation) and has started India clinical studies, targeting FY28 launch.
• First ADC biosimilar entering clinic: The company’s first antibody-drug conjugate biosimilar is on track to enter human studies in FY27.
• CDMO program count is undisclosed but advancing: Management will not disclose the total number of programs, but volunteered that 3 late-stage NCE programs will enter commercialization in FY28. Over 6 active large-molecule NCE programs are running with various partners, and one will enter human clinical studies in FY27 through its partner.
• CDMO economics can be lumpy and outsized: In select contracts, Shilpa has taken equity or profit-share stakes in smaller biotech partners. If those programs succeed, the outcome is materially higher than a standard CDMO contract, but failures are budgeted and hit the P&L directly.
• Integrated capability is the moat: Management argues that few Indian companies can offer small molecules, large molecules, API, payloads, linkers, conjugation, ADCs, and Mabs under one roof, positioning Shilpa as a differentiated CDMO partner.

Alpesh Dalal: "Its not the case that every program we work on is successful. There are also some failures that we have to budget for, and that goes straight to our P&L as a hit."

API: Steady Base, Peptide Bet

The API division provides the steady foundation, with a new peptide manufacturing investment signaling the next growth vector.

• 15% YoY revenue growth: Improved offtake of key products from newly expanded capacities, plus strong captive demand from the formulations division, drove the increase.
• Specialty CDMO traction: Within API, the specialty CDMO sub-segment gained new clients in developed markets.
• Peptide manufacturing capex: A large capital investment in peptide manufacturing capacity in India, with solid-phase synthesis capability from start to end, will complete commissioning by the end of FY27.
• Oncology API is customer-backed: For each oncology API product, there is already an identified end customer before investment is made, reducing demand risk. Growth trajectory depends on how those molecules translate at the end-customer level.
• Overall API outlook: Steady growth is likely in FY27.

Nor-UDCA: The Wildcard Asset

Nor-UDCA, a novel therapy for liver fibrosis, is the company’s highest-visibility proprietary asset. Management is bullish on its differentiated mechanism but tightly controls the information flow.

• Mechanism differentiation: Nor-UDCA directly targets the liver enzyme, a mechanism completely distinct from products like semaglutide that are also being studied for liver fibrosis.
• Global development advancing: European and U.S. scientific adviser meetings have been successfully completed, and global Phase II clinical studies will start in FY27.
• Current revenue is material but undisclosed: An analyst estimated domestic formulation revenue at ~INR59 crores over the last two quarters and asked how much came from Nor-UDCA; management declined to provide any product-level sales numbers.
• Clinical data is public but not elaborated: When asked to elaborate on positive clinical data, management pointed to published online data and said Phase IV data will be published when available, without offering specifics on the call.
• Order visibility is strong for FY27: Management stated there is strong visibility of orders for the current fiscal year.

Keshav Bhutada: "The mechanism of action of Nor-UDCA and that of any other product currently under study is completely different. Nor-UDCA directly targets the liver enzyme. That is the major advantage this product has against products like semaglutide, which has a different mechanism of action for liver fibrosis."

Margins & Financials

Margins held near the 30% level that management has consistently delivered, though raw material costs and the inherent lumpiness of licensing income create quarter-to-quarter variability.

• EBITDA margin around 30%: Management has consistently maintained this level and wants to stay conservative, expecting margins to remain in a similar range rather than guiding to expansion.
• Gross margin dipped slightly: The dip was partly driven by global political conditions pushing up raw material prices; only part of the increase can be passed to customers. Management said it is difficult to quantify what gross margin would be if raw material prices normalized.
• Licensing income is high-margin but lumpy: Licensing income carries significantly higher margins than the spend incurred, but spend is upfront and revenue may come later. Not every program succeeds, and failures are a direct P&L hit.
• Negative tax rate was a one-time adjustment: The quarter’s negative tax rate resulted from a reversal of deferred tax liability as the company plans to switch to the new tax regime, which carries a lower tax incidence. The rate is expected to normalize around 25% in coming quarters.
• Upcoming launches are margin-accretive: The near-term pipeline (Rotigotine patch, Abraxane, Nor-UDCA, 505(b)(2)s with no generics) consists entirely of complex products that drive higher gross margins than commoditized generics.

Alpesh Dalal: "At this stage, I wouldn't want to raise expectations too high. We would like to be conservative and overdeliver. So we would expect margins to remain in a similar range."

Risks & What Management Won’t Disclose

Management declined to answer a notable number of analyst questions, particularly around product-level revenue splits, division-level R&D budgets, and capacity utilization. The regulatory risk flag was raised by the CFO himself.

• Regulatory risk is self-identified: The CFO volunteered that while the company works to be robust and compliant, regulatory authorities may occasionally take a different view, and unexpected challenges could slow the growth trajectory.
• Product-level revenue is off-limits: Management declined to disclose Nor-UDCA sales contribution, licensing vs product revenue splits, and segment-wise gross margins, limiting investors’ ability to model the sustainability of formulation growth.
• Division-level R&D and capex detail is withheld: R&D investment splits by division and plant-level capacity utilization were not disclosed; analysts were directed to the IR team offline.
• CDMO program count and partner details are confidential: The number of CDMO programs, the identity of the 2 new Japanese customers, and the specifics of the Orion deal (launch year, peak revenue) were all declined on confidentiality grounds.
• Unicycive CRL adds uncertainty: The partner received a Complete Response Letter from USFDA and plans to refile in Q3; Shilpa is working closely with the partner on next steps, but the timeline is now dependent on the agency’s response.

Alpesh Dalal: "Whilst we are working towards being very robust and compliant with our practices, once in a while, the way regulatory authorities look at us could be a bit different. And if some of those unexpected challenges come up, that might slow down the growth trajectory that we have."

Guidance & Commitments

Key Metrics